RERE-AS1 as a regulator of immune modulation and therapeutic response in breast cancer Authors: Shaohui Jiang, Weijie He, Zhimin Li, Haodong He, Yuehua Li, Meiling Wen, Hongbo Zhu, Pengfei Luo Published: 2025 ABSTRACT AbstractBackground and aimsBreast cancer (BRCA) remains one of the most prevalent malignancies and a major threat to women’s health worldwide. The biological role and mechanistic basis of the long non-coding RNA (lncRNA) RERE-AS1 in BRCA remain unclear.MethodsClinical and RNA sequencing data from BRCA patients were analyzed to determine RERE-AS1 expression levels. RNA fluorescence in situ hybridization (FISH) was used to visualize its distribution in tumor tissues. Functional assays were conducted in MCF-7 and T47D cells to assess the effects of RERE-AS1 on cellular proliferation, migration, invasion, and apoptosis using Cell Counting Kit-8 (CCK-8), Transwell assays, and flow cytometry. Cell cycle progression was also evaluated. A co-culture system of BRCA cells and immune cells was established to examine immune cell migration, lactate dehydrogenase (LDH) release, and immune cytotoxicity. Cytokine secretion was quantified via enzyme-linked immunosorbent assay (ELISA). Furthermore, a xenograft mouse model was utilized to confirm the impact of RERE-AS1 on tumor growth and its response to anti-PD-1 therapy.ResultsRERE-AS1 expression was markedly decreased in BRCA tissues and correlated with overall survival (OS), tumor stage, and immune infiltration levels. Functional experiments demonstrated that RERE-AS1 overexpression inhibited BRCA cell proliferation, migration, and invasion while inducing apoptosis and cell cycle arrest. Additionally, RERE-AS1 strengthened the interaction between BRCA and immune cells, reduced immune escape, and enhanced tumor sensitivity to immune checkpoint blockade therapy.ConclusionRERE-AS1 acts as a promising prognostic biomarker and potential therapeutic target in BRCA. Its expression is closely associated with disease progression and patient outcomes and plays a regulatory role in tumor cell behavior and immune microenvironment modulation.Clinical relevance statementThis study identifies RERE-AS1 as a critical regulator of tumor-immune interactions, suggesting its potential for guiding precision immunotherapy and prognostic assessment in BRCA patients.Graphical abstract Supplementary InformationThe online version contains supplementary material available at 10.1007/s00262-025-04211-z.Keywords: Breast cancer, RERE-AS1, Immune infiltration, Bioinformatics, Immune evasion, Immune checkpoint inhibitor Introduction Breast cancer (BRCA) is a major malignancy among women globally. Its steadily increasing incidence and mortality impose profound physical and psychological distress on patients and families while exerting a significant socioeconomic burden [1–4]. In a city in China, the treatment cost for BRCA reached as high as 2.7338 trillion RMB in 2018, accounting for 10.66% of total cancer-related expenditures [1]. Despite substantial progress in the diagnosis and treatment of BRCA in recent years, patient survival remains unsatisfactory, particularly in regions with limited economic resources [5–7]. Epidemiological data indicate that the 5 year survival rate decreases sharply as the disease advances, dropping from approximately 90% in early stages to nearly 20% in advanced cases [8, 9]. These observations highlight the urgent need to elucidate the molecular mechanisms driving BRCA progression, clarify their clinical relevance, and identify reliable biomarkers to guide the development of more effective and individualized therapeutic strategies. In this context, the long non-coding RNA (lncRNA) RERE-AS1 has recently attracted increasing attention from researchers [10]. As a key RNA gene, RERE-AS1 plays critical roles in various biological processes (BP), including organ development, cell growth, and apoptosis [11–13]. Previous studies have primarily emphasized RERE deficiency, which has been associated with cardiac dysfunction, neurodevelopmental abnormalities, and asymmetric body development [10, 14, 15]. However, investigations into the specific expression patterns, biological functions, and potential clinical applications of RERE-AS1 in BRCA remain limited. A comprehensive investigation into the role of RERE-AS1 in BRCA could deepen understanding of the molecular mechanisms governing tumor initiation and progression, offering promising avenues for improved diagnosis and targeted therapy. Utilizing data from The Cancer Genome Atlas (TCGA) and other publicly available databases, this study explored the expression profile, biological significance, and immunological relevance of RERE-AS1 in BRCA). Through a combination of bioinformatics analysis and RNA fluorescence in situ hybridization (FISH), the expression pattern of RERE-AS1 in malignant BRCA tissues was examined and validated, providing insight into its involvement in tumor initiation, progression, and clinical outcomes. Furthermore, the prognostic potential of RERE-AS1 and its relationship with immune cell infiltration were systematically evaluated. This study further integrates clinical data with in vitro and in vivo experiments to elucidate the functional role of RERE-AS1 within the tumor immune microenvironment. By bridging molecular and pathological findings, we aim to establish a comprehensive understanding of RERE-AS1-mediated regulation in BRCA. The ultimate goal is to identify reliable molecular biomarkers for early diagnosis, therapeutic decision-making, and prognostic assessment, thereby contributing to the advancement of precision medicine in BRCA management. Materials and methods Transcriptome data acquisition and processing Transcriptome sequencing data were obtained from TCGA (https://www.tcga.org) as of January 2022, including 1,083 BRCA tumor samples and 113 normal tissue samples. Data formats included HTSeq-FPKM and HTSeq-Counts. Samples with incomplete clinical, sequencing, or follow-up information were excluded. Data were normalized using variance-stabilizing transformation (VST) or regularized log (rlog) transformation provided by the DESeq2 package to reduce technical noise and mitigate differences in sequencing depth. Quality control was performed by assessing the uniformity of data distribution to ensure the absence of systematic bias. Clinical and pathological characteristics, including age, sex, and disease progression status, were integrated into the dataset (Table 1). Table 1Relationship between RERE-AS1 expression and the clinicopathological characteristics of breast cancer patientsCharacteristicLow expression of RERE-AS1High expression of RERE-AS1pn541542T stage, n (%) < 0.001T1104 (9.6%)173 (16%)T2350 (32.4%)279 (25.8%)T361 (5.6%)78 (7.2%)T424 (2.2%)11 (1%)N stage, n (%)0.861N0249 (23.4%)265 (24.9%)N1184 (17.3%)174 (16.4%)N257 (5.4%)59 (5.5%)N338 (3.6%)38 (3.6%)M stage, n (%)0.609M0466 (50.5%)436 (47.3%)M112 (1.3%)8 (0.9%)Pathologic stage, n (%)0.003Stage I68 (6.4%)113 (10.7%)Stage II327 (30.8%)292 (27.5%)Stage III121 (11.4%)121 (11.4%)Stage IV11 (1%)7 (0.7%)Race, n (%)0.037Asian39 (3.9%)21 (2.1%)Black or African American84 (8.5%)97 (9.8%)White367 (36.9%)386 (38.8%)Age, n (%)0.311 < = 60309 (28.5%)292 (27%) > 60232 (21.4%)250 (23.1%)Histological type, n (%) < 0.001Infiltrating Ductal Carcinoma430 (44%)342 (35%)Infiltrating Lobular Carcinoma61 (6.2%)144 (14.7%)PR status, n (%)0.052Negative188 (18.2%)154 (14.9%)Indeterminate2 (0.2%)2 (0.2%)Positive326 (31.5%)362 (35%)ER status, n (%)0.279Negative125 (12.1%)115 (11.1%)Indeterminate2 (0.2%)0 (0%)Positive389 (37.6%)404 (39%)HER2 status, n (%)0.021Negative269 (37%)289 (39.8%)Indeterminate3 (0.4%)9 (1.2%)Positive91 (12.5%)66 (9.1%)PAM50, n (%) < 0.001Normal10 (0.9%)30 (2.8%)LumA249 (23%)313 (28.9%)LumB131 (12.1%)73 (6.7%)Her249 (4.5%)33 (3%)Basal102 (9.4%)93 (8.6%)Menopause status, n (%)0.610Pre117 (12%)112 (11.5%)Peri22 (2.3%)18 (1.9%)Post341 (35.1%)362 (37.2%)Anatomic neoplasm subdivisions, n (%)0.107Left295 (27.2%)268 (24.7%)Right246 (22.7%)274 (25.3%)radiation_therapy, n (%)0.024No230 (23.3%)204 (20.7%)Yes252 (25.5%)301 (30.5%)Age, median (IQR)58 (48, 67)59 (49, 67)0.282The bold values indicates statistically significant results with p 0.05 Relationship between RERE-AS1 expression and the clinicopathological characteristics of breast cancer patients The bold values indicates statistically significant results with p 0.05 RERE-AS1 expression pattern analysis The expression levels of RERE-AS1 across multiple tumors and normal tissues were analyzed using TPM-formatted RNA-seq data uniformly processed through the Toil pipeline on the UCSC Xena platform. The Toil pipeline encompassed data acquisition, quality control, alignment, transcript quantification, integration, and normalization to ensure cross-cohort comparability. After obtaining consistent and high-quality data, differential expression of RERE-AS1 across various cancer types, including BRCA, was examined. Its potential associations with clinical parameters, including survival status and disease progression in BRCA patients, were further evaluated. FISH and immunofluorescence detection RERE-AS1 expression was detected using FISH. A fluorescently labeled single-stranded RNA probe targeting RERE-AS1 (sequence: GAGGGAGAGCCCAGCAGAAGCAGCTCAGGGCTTCAAAGACACGTCTTTAGGCAAGCCGGACTGTTTA/CTGTAGCACCTCTCCATCCCTGATAATGGCTGGGGACTAGAATAGCTAG) was designed and synthesized for hybridization with triple-negative BRCA tissues and matched normal breast tissues. Probe design, synthesis, and hybridization conditions were optimized to ensure specificity and signal intensity. Paraffin-embedded sections were deparaffinized in xylene, rehydrated, and incubated in 2 × SSC ( 37 °C, 1 h). Sections were digested with pepsin working solution (20 μL of 10% pepsin in 40 mL of 0.01 N HCl) for 13 min at 37 °C, rinsed in PBS, and fixed with 0.95% formaldehyde (prepared with 1 mL of 37% formaldehyde, 0.18 g MgCl₂, and 39 mL PBS) for 5 min at ambient temperature. After sequential dehydration in 70, 85, and 100% ethanol, denaturation was carried out in pH 7.0–8.0 solution at 73 ± 1 °C for 30 min. Ten microliters of hybridization mixture were applied, covered, and incubated at 37 °C for 6–24 h in a humidified chamber. Post-hybridization washes were performed in 0.4 × SSC/0.3% NP-40 at 73 ± 1 °C for 2 min, followed by 2 × SSC/0.1% NP-40 at ambient temperature for 1 min. Sections were briefly rinsed, air-dried, counterstained with DAPI, and mounted. Fluorescence images were captured using a Zeiss Axiovert 123 M microscope, and RERE-AS1 expression levels were quantified by ImageJ analysis based on fluorescence intensity. Correlation analysis between RERE-AS1 expression and clinical characteristics in BRCA The association between RERE-AS1 expression and clinicopathological parameters in BRCA was analyzed using RNA sequencing data from the TCGA-BRCA cohort. Samples were ranked by RERE-AS1 expression levels and divided into high- and low-expression groups according to the median value. The Wilcoxon rank-sum test was applied to assess associations between RERE-AS1 expression and clinical variables, including T stage (T1–T4), pathological stage (Stage I–IV), PR status (negative/positive), HER2 status (negative/positive), PAM50 molecular subtype (LumA, LumB, Her2, Basal), histological type (IDC, ILC), and radiotherapy status (untreated/treated). Statistical significance was defined as p < 0.05. Kaplan–Meier survival analysis The prognostic significance of RERE-AS1 expression in BRCA was analyzed using the Kaplan–Meier Plotter online platform, which integrates RNA-seq data, survival information, and HTSeq counts from multiple public databases, including TCGA. Patients were categorized into high- and low-expression groups based on median RERE-AS1 expression levels. Disease metastasis-free survival (DMFS), Overall Survival (OS), and relapse-free survival (RFS) curves were generated, and survival differences were assessed by the log-rank test. Results were presented as hazard ratios (HR) with 95% confidence intervals (CI). A Cox proportional hazards regression model was additionally employed to determine whether RERE-AS1 expression served as an independent prognostic factor for OS. A two-sided p-value < 0.05 was considered statistically significant. Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis Genes correlated with RERE-AS1 expression were subjected to functional and pathway enrichment analysis. RNA sequencing data from the TCGA-BRCA cohort were normalized using the DESeq2 package, and samples were divided into high- and low-expression groups based on the median RERE-AS1 level. Differentially expressed genes (DEGs) were identified using DESeq2 with thresholds of |log2(FC)|> 1.5 and adjusted p < 0.05, followed by clustering-based filtering. GO and KEGG enrichment analyses were performed using the clusterProfiler R package. GO analysis encompassed three categories: BP, cellular components (CC), and molecular functions (MF). KEGG analysis identified signaling and metabolic pathways associated with BRCA. Pathways with a false discovery rate (FDR) < 0.05 were considered significantly enriched and further evaluated for their potential involvement in RERE-AS1-mediated tumor progression. Gene set enrichment analysis (GSEA)-based gene enrichment analysis Cluster-based GSEA was carried out to investigate subtype-specific gene expression patterns associated with RERE-AS1 expression. Genes were ranked using the clusterProfiler R package, and enrichment analysis was conducted based on RERE-AS1 expression levels. The reference gene set was obtained from the Molecular Signatures Database (MSigDB) c2.cp.kegg.v7.1.symbols file, which contains annotated signaling and metabolic pathways from the KEGG database. For each analysis, 1000 gene set permutations were performed. Pathways with an FDR < 0.25 and a p-value < 0.05 were considered statistically significant in order to improve sensitivity and capture potential biological signals. Single-Sample gene set enrichment analysis (ssGSEA)-based immune infiltration analysis ssGSEA was conducted to estimate the abundance of tumor-infiltrating lymphocytes (TILs) in BRCA using RNA sequencing data from the TCGA cohort. Enrichment scores for 24 immune cell types were calculated with the GSVA R package (v1.34.0). Immune signature gene sets representing T cells, B cells, natural killer (NK) cells, macrophages, and other immune subsets were obtained from published data [16]. Differences between high and low RERE-AS1 expression groups were evaluated using the Wilcoxon rank-sum test, and correlations between RERE-AS1 expression and immune cell infiltration were assessed by Spearman’s rank correlation analysis. Immune microenvironment scoring (ESTIMATE) The R package estimate (v1.0.13) was applied to RNA sequencing data from the TCGA-BRCA cohort to evaluate stromal components and immune cell infiltration in BRCA tissues. Raw count matrices were converted to TPM values followed by log2(TPM + 1) transformation. The filterCommonGenes function was used to select common genes and generate gct files, and the estimateScore function was applied to calculate StromalScore, ImmuneScore, and ESTIMATEScore. Based on the published formula [17], tumor purity was inferred from the ESTIMATEScore as: Tumor purity = cos(0.6049872018 + 0.0001467884 × ESTIMATEScore). The resulting scores were compared between high and low RERE-AS1 expression groups and integrated with clinical and immune infiltration data for comprehensive assessment. Cell culture and treatment Human BRCA cell lines MCF-7 (Cat. No. HTB-22) and T47D (Cat. No. HTB-133) were obtained from the American Type Culture Collection (ATCC, USA). Both cell lines were cultured in RPMI-1640 medium (11,875,101, Gibco, USA) supplemented with 10% fetal bovine serum (FBS, 16,140,089, Gibco, USA) in a humidified incubator at 37 °C with 5% CO2. Human peripheral blood mononuclear cells (hPBMCs, Cat. No. CP-H182) were purchased from Wuhan Pricella Biotechnology Co., Ltd. (Hubei, China) and maintained in RPMI-1640 medium (11,875,101, Gibco, USA) containing 10% FBS, 100 U/mL penicillin, and 100 U/mL streptomycin (PB180120, Wuhan Pricella Biotechnology Co., Ltd.). Monocytes were cultured in RPMI-1640 enriched with 10% FBS and 10 ng/mL recombinant human GM-CSF (PHC2013, Gibco, USA) for 7 days to induce differentiation into M1/M2 macrophages or dendritic cells (DCs). In vivo xenograft model and treatment Six-week-old female humanized NOD/SCID mice (NSG™-SGM3, Cat. No. 005557) were obtained from the Shanghai Experimental Anial Center, Chinese Academy of Sciences (License No. SCXK-2019-0012). All mice exhibited peripheral blood human CD45+ chimerism above 25% and were housed under specific pathogen-free (SPF) conditions (22 ± 1 °C, 12 h light/dark cycle). MCF-7 cells (5 × 105, ATCC HTB-22; STR authentication provided in Supplementary Materials) transduced with lentiviruses (sh-RERE-AS1 or sg-RERE-AS1) were subcutaneously inoculated into the right flank. To support tumor growth, mice were implanted with a 0.72 mg 17β-estradiol sustained-release pellet (Innovative Research, SE-121) 48 h prior to inoculation. Mice were randomly divided into eight groups (n = 5 per group): sh-NC + IgG, sh-NC + αPD-1, sh-RERE-AS1 + IgG, sh-RERE-AS1 + αPD-1, sg-NC + IgG, sg-NC + αPD-1, sg-RERE-AS1 (KI) + IgG, and sg-RERE-AS1 (KI) + αPD-1. In αPD-1 treatment groups, the humanized PD-1 monoclonal antibody Pembrolizumab (5 mg/kg, intraperitoneal injection, once weekly; Merck, MSQC24) was administered. Control groups received Human IgG4κ (BioXcell, BP0089). After 28 days of treatment, mice were euthanized, and tumor tissues were collected for downstream analyses [18]. Immunohistochemistry Tumor tissues were formalin-fixed, paraffin-embedded, and sectioned at 4 μm. Sections were deparaffinized, hydrated through graded alcohols, and subjected to microwave antigen retrieval in citrate buffer (92–98 ℃, 15 min), then cooled and rinsed in PBS (3 × 3 min). Endogenous peroxidase activity was blocked with 3% hydrogen peroxide (15 min, room temperature), followed by PBS washing. After encircling tissue with a hydrophobic pen, 5% FBS was applied for 1 h at ambient temperature to block nonspecific binding. Sections were incubated with anti–Ki-67 primary antibody (1:500, Abcam) overnight at 4 ℃ in a humid chamber; PBS was used instead of primary antibody for negative controls. After washing, sections were incubated with HRP-conjugated secondary antibody (1:2000, Abcam) for 30 min at ambient temperature, rinsed (4 × 3 min PBS), and developed with freshly prepared DAB substrate until brownish staining appeared, with microscopic monitoring to avoid overdevelopment. Counterstaining was performed with hematoxylin (~ 30 s), followed by rinsing, differentiation in 1% acid alcohol, and bluing in tap water. Finally, sections were dehydrated, mounted, and observed microscopically. Lentiviral vector construction Lentiviral interference vectors (pSIH1-H1-copGFP, Cat. No. SI501A-1, System Biosciences, USA) were used to construct RERE-AS1 knockdown and negative control vectors. Viral particles were packaged in HEK-293 T cells (iCell-h237, iCellBioscience, China) using a packaging kit (A35684CN, Invitrogen, USA), and supernatants were collected after 48 h at a titer of ~ 1 × 108 TU/mL. MCF-7 and T47D cells (1 × 105 cells/well in 6-well plates) were infected at 60–70% confluence with lentiviral particles (MOI = 10, working titer ~ 1 × 106 TU/mL) in the presence of 5 μg/mL polybrene (TR-1003, Merck, USA). After 4 h of transduction, the medium was refreshed and replaced after 24 h. Stable cell lines were selected with 1 μg/mL puromycin (A1113803, Thermo Fisher Scientific, USA) for 48 h. The sequences used for transduction are listed in Table S1, and knockdown efficiency was confirmed by RT-qPCR. CRISPR-Cas9 gene editing and cell grouping CRISPR/Cas9 technology was employed to generate RERE-AS1-overexpressing MCF-7 and T47D cell lines. Two sgRNAs targeting exon X of RERE-AS1 were designed (Fig. S1A), with sequences provided in Table S2. The knock-in fragment sequence and its genomic localization are shown in Fig. S1A. The sgRNAs were cloned into the Lenti-CRISPR v2 vector (Hanbio Biotechnology, Shanghai, China) carrying the Streptococcus pyogenes Cas9 nuclease. Lentiviral particles were produced and used to transduce MCF-7 and T47D cells, establishing stable RERE-AS1-overexpressing lines via the CRISPR/Cas9 system. Following transduction, cells were selected with 4 μg/mL puromycin (540,222, Sigma-Aldrich, USA). Surviving cells were subjected to single-cell cloning by limiting dilution, and RT-qPCR was performed to confirm RERE-AS1 overexpression in selected clones. For experimental purposes, cells were divided into four groups: sh-NC (negative control for knockdown), sh-RERE-AS1 (RERE-AS1 knockdown), sg-NC (negative control for overexpression), and sg-RERE-AS1 (KI, RERE-AS1 overexpression). Quantitative reverse transcription polymerase chain reaction (qRT-PCR) Total RNA was isolated from tissues using TRIzol reagent (16,096,020, Invitrogen, USA). Complementary DNA (cDNA) was synthesized using a reverse transcription kit (RR047A, Takara, Japan), and quantitative PCR was performed with TaqMan Gene Expression Assays (Applied Biosystems, USA), using GAPDH as an internal control. Reactions were conducted on an ABI 7500 Real-Time PCR System (Thermo Fisher Scientific, USA). Relative gene expression was calculated using the 2–ΔΔCt method. All experiments were performed in triplicate and independently repeated three times. Primer sequences are listed in Table S3, and corresponding Cq values in Table S4. Cell sorting by flow cytometry Patient-derived xenograft (PDX) or mouse tumor tissues containing mixed populations of human tumor cells, human immune cells, and murine stromal cells were processed to isolate human tumor cells (MCF-7 as an example) using fluorescence-activated cell sorting (FACS). Tumor tissues were minced and digested in 1 mg/mL collagenase IV (Sigma, C5138) and 10 μg/mL DNase I (Roche, 10,104,159,001) at 37 °C for 30 min with vortexing every 10 min. The digested suspension was filtered through a 40 μm cell strainer, centrifuged (300 × g, 5 min), and the pellet was treated with ACK lysis buffer (Gibco, A1049201) for 2 min to remove red blood cells, followed by PBS wash. Single-cell suspensions were resuspended in PBS, filtered through nylon mesh, and prepared for flow cytometry. Cells were incubated for 1 h at ambient temperature in the dark with validated human-specific antibody panels: CD16-FITC and CD56-APC for NK cells, CD19-FITC and CD20-APC for B cells, CD80-APC and CD86-FITC for M1 macrophages, CD163-APC and CD206-FITC for M2 macrophages, and CD11c-FITC and CD141-APC for dendritic cells (all Abcam, UK). After washing with PBS, samples were analyzed and sorted on a BD FACS Aria III (BD Immunocytometry Systems, USA). Sorting purity was required to be > 95%. Primary MCF-7 cells were further verified by STR profiling (Supplementary Materials) and cultured in RPMI-1640 medium enriched with 10% FBS, with passages limited to ≤ 3 for downstream experiments. Cell co-culture system MCF-7 (HTB-22) and T47D (HTB-133) BRCA cells (≤ 5 passages) were obtained from ATCC and synchronized in serum-free medium for 6 h before seeding. NK-92 cells (Procell, CL-0530) were cultured in α-MEM supplemented with 100-U/mL IL-2. Peripheral blood–derived B cells (Procell, CP-H158) were isolated by negative selection with CD19+ magnetic beads (Miltenyi, 130-050-301). Macrophages were generated from peripheral blood monocytes (Procell, CP-H264) by induction with GM-CSF (100 ng/mL, PeproTech, 300–03) for 5 days to obtain M0 cells, followed by polarization with IFN-γ (20 ng/mL, PeproTech, 300–02) plus LPS (100 ng/mL, Sigma, L4391) for 24 h to obtain M1 cells, or IL-4 (20 ng/mL, PeproTech, 200–04) for 24 h to obtain M2 cells. Dendritic cells (DCs) were derived from peripheral blood CD14+ cells (Miltenyi, 130–050-201) cultured with GM-CSF and IL-4 (each 50 ng/mL) for 7 days. For co-culture, Transwell chambers (0.4 μm, Corning 3412) were used. The upper chamber was seeded with MCF-7 or T47D cells (1 × 105/mL, 1.5 mL, serum-free RPMI-1640), while the lower chamber contained immune cells (1 × 105/mL, 1.5 mL, RPMI-1640 with 10% FBS). After 48 h of co-culture, immune cells from the lower chamber were collected for flow cytometry analysis (activation/subset profiling), and supernatants were harvested for ELISA-based cytokine measurement. All co-culture experiments were performed in both MCF-7 and T47D systems in parallel. Cell proliferation assay using cell counting kit-8 (CCK-8) Cell proliferation was evaluated using a CCK-8 assay kit (WH1199, Shanghai Weiao Biotechnology, China). MCF-7 and T47D cells in the logarithmic growth phase were seeded into 96-well plates at 5 × 104 cells/mL (100 μL per well) and incubated for 24, 48, and 72 h. At each time point, 10 μL of CCK-8 reagent was added, followed by incubation at 37 °C for 2 h. Absorbance was measured at 450 nm using a Multiskan FC microplate reader (51,119,080, Thermo Fisher Scientific, USA). Each group contained three replicate wells, and all experiments were independently repeated three times. Celltiter-Glo assay At the designated experimental endpoints, CellTiter-Glo reagent (G7570, Promega, USA) was added to the culture medium of MCF-7 or T47D cells co-cultured with RERE-AS1 knockdown, overexpression, or control groups. After gentle shaking and incubation to stabilize the luminescent signal, intracellular ATP levels were measured using a luminometer, serving as an indicator of cell viability and proliferation. Transwell assay for cell migration and invasion Cell migration was evaluated using Transwell chambers (8 μm pore size, Corning). Immune cell suspensions (200 μL) were seeded in the upper chamber, and 800 μL of conditioned medium containing 20% FBS and differentially transfected MCF-7 or T47D cells was added to the lower chamber. After incubation at 37 °C for 24 h, non-migrated cells on the inner membrane surface were gently removed with a cotton swab. The membranes were washed with PBS, fixed in 4% paraformaldehyde, and stained with 0.1% crystal violet for 30 min. Migrated cells were visualized under a Nikon Eclipse Ci microscope (Nikon, Japan), and the mean number of cells in five random fields was calculated. Each experiment was repeated three times. For invasion assays, membranes were pre-coated with Matrigel (354,234, Corning, USA) before cell seeding, and subsequent procedures were identical to those for migration assays. Cell viability and lactate dehydrogenase (LDH) activity assay LDH levels were measured in the MCF-7 or T47D co-culture systems using an LDH activity assay kit (Cat. No. C0016, Beyotime, Shanghai, China). As LDH is released upon membrane damage, its activity was used to assess cytotoxicity. Absorbance was recorded at 490 nm to quantify LDH activity. ELISA Culture supernatants from MCF-7 or T47D co-cultures were collected by centrifugation at 1,000 × g for 10 min at ambient temperature. The concentrations of IFN-γ (97024ES48, Yeasen Biotechnology, Shanghai, China), TNF-α (HET019, Shanghai Bogoo Biotechnology, Shanghai, China), and IL-10 (EH10245S, Shanghai Weiao Biotechnology, Shanghai, China) were determined using commercial ELISA kits. Flow cytometry for cell cycle analysis Treated MCF-7 and T47D cells were harvested and resuspended in 400 μL propidium iodide (PI) staining solution (50 μg/mL, P4170, Sigma-Aldrich, USA) containing 100 μL RNase A (100 μg/mL, RNASEA-RO, Sigma-Aldrich, USA). After incubation at 4 °C for 30 min in the dark, samples were analyzed using a BD flow cytometer (BD Biosciences, USA). Cell cycle distribution was determined with ModFit software. All experiments were performed in triplicate. Flow cytometry for apoptosis analysis Apoptosis was quantified using Annexin V-FITC/PI dual staining (Annexin V-FITC Apoptosis Detection Kit, 556,547, BD Biosciences, USA). MCF-7 and T47D cells were collected, washed twice with PBS, and resuspended in 500 μL binding buffer. After adding 5 μL Annexin V-FITC and 5 μL PI, cells were incubated for 15 min in the dark and analyzed on a BD FACSCalibur flow cytometer. Annexin V-FITC–positive cells were identified as apoptotic. Each experiment was conducted in triplicate. Western blot Total protein was extracted from tissues and MCF-7 or T47D cells using RIPA lysis buffer containing 1% PMSF (P0013B, Beyotime, Shanghai, China). Protein concentrations were determined with a BCA assay kit (P0011, Beyotime, Shanghai, China), adjusted to 1 μg/μL, and aliquoted (100 μL per tube). Samples were denatured by boiling at 100 °C for 10 min and stored at − 80 °C until use. Equal amounts of protein (50 μg) were loaded onto 8–12% SDS-PAGE gels and separated under constant voltage (80 V, followed by 120 V for 2 h). Proteins were transferred to PVDF membranes (1,620,177, Bio-Rad, USA) using a wet transfer system (250 mA, 90 min). Membranes were blocked with 5% non-fat milk in TBST for 1 h at ambient temperature, followed by incubation overnight at 4 °C with the following primary antibodies (all from Abcam, Cambridge, UK): E-cadherin (ab314063, 1:1000), N-cadherin (ab245117, 1:2000), ZO-1 (ab30779, 1:1000), MMP2 (ab92536, 1:1000), Cyclin A1 (ab270940, 1:1000), Cyclin B1 (ab181593, 1:2000), Cyclin D2 (ab308258, 1:1000), cleaved Caspase-3 (ab214430, 1:2000), Bax (ab32503, 1:1000), Bcl-2 (ab182858, 1:1000), and GAPDH (ab9485, 1:2000) as the internal control. After three washes with TBST (10 min each), membranes were incubated with HRP-conjugated goat anti-rabbit IgG (ab6721, 1:5000, Abcam) or goat anti-mouse IgG (ab205719, 1:5000, Abcam) for 1 h at ambient temperature, followed by three additional TBST washes (5 min each). Protein bands were visualized using ECL detection reagent (1,705,062, Bio-Rad, USA) and imaged with an ImageQuant LAS 4000C system (GE Healthcare, USA). GAPDH served as the internal loading control. All experiments were performed in triplicate. Statistical analysis All statistical analyses were performed using R software (version 4.0.2). Differences in RERE-AS1 expression between tissues were assessed using the Wilcoxon rank-sum or signed-rank tests. Associations between RERE-AS1 expression and clinicopathological parameters were analyzed with the Kruskal–Wallis or Wilcoxon signed-rank tests, and logistic regression models were used to assess correlations with clinical variables. Diagnostic performance was determined by receiver operating characteristic (ROC) curve analysis, and nomograms were constructed to predict 1, 3, and 5 year OS. For cell-based experiments, differences between migration and invasion assay groups were analyzed using Student’s t-test or one-way analysis of variance (ANOVA). Cell cycle and apoptosis data were evaluated using the chi-square test or Fisher’s exact test. Experiments involving multiple time points or doses were assessed using repeated-measures ANOVA or mixed-effects models to account for interactions between treatment and time or dose. All experiments were performed in triplicate. A p-value < 0.05 was considered statistically significant, and p < 0.01 was considered highly significant. Results LncRNA RERE-AS1 is downregulated across multiple cancer types, particularly in BRCA Analysis of transcriptome data from 33 tumor types and corresponding normal tissues in the TCGA database demonstrated that RERE-AS1 expression was significantly downregulated in multiple cancers, including BRCA, COAD, KICH, KIRC, LIHC, LUSC, PCPG, PRAD, and THCA, with a decreasing trend also observed in LAML (Figure S2A, B). In the paired analysis of 18 tumor types and their adjacent normal tissues, RERE-AS1 expression was reduced in BRCA, KICH, and LUSC, but increased in KIRC (Figure S2C, Table 2). Table 2Significant expression differences analysis results between TCGA tumors and normal samplesGroup 1Group 2CountMedianInterquartile range (IQR)MeanStandard deviation (SD)Standard error (SE)BRCANormal1120.1950.3920.2290.2090.02BRCATumor1120.0630.1410.1080.1650.016KICHNormal250.1380.1050.1380.1130.023KICHTumor25000.0290.0620.012KIRCNormal720.0980.1790.1130.1130.013KIRCTumor720.1510.1420.1620.1310.015 Significant expression differences analysis results between TCGA tumors and normal samples In BRCA, RERE-AS1 expression was lower in 1,109 tumor samples than in 113 normal tissues (median: 3.564 vs. 3.729; p = 2.9 × 10−27) (Fig. 1A). Integration with GTEx data confirmed marked downregulation of RERE-AS1 in BRCA tissues (median: 2.260 vs. 2.755; p = 1.5 × 10−61) (Fig. 1B). Among 112 paired BRCA and adjacent normal tissues, expression was likewise significantly decreased (3.500 ± 0.365 vs. 3.773 ± 0.674; p = 1.1 × 10–16) (Fig. 1C). In addition, RNA-FISH detection showed markedly weaker RERE-AS1 signals in BRCA tissues compared with non-malignant breast tissues, further supporting its reduced expression at the tissue level (Fig. 1D, D). Localization and Expression Analysis of RERE-AS1 Across Multiple Tumor Types and in BRCA. A–C RERE-AS1 mRNA expression in breast cancer and normal tissues based on TCGA and GTEx datasets, including A unpaired samples, B comparison with normal tissue samples, and C 112 paired breast cancer and adjacent normal tissues. D–E RNA-FISH detection of RERE-AS1 localization and expression, including D breast cancer tissues and E adjacent non-malignant tissues (red signals, scale bar = 50 μm). Clinical samples were obtained from the First Affiliated Hospital, Hengyang Medical School, University of South China, with ethical approval.. The Wilcoxon rank-sum test determines statistical significance. *p < 0.05, **p < 0.01, ***p < 0.001; ns indicates no statistically significant difference compared with the control or normal group Correlation analysis between RERE-AS1 expression and clinical characteristics in BRCA In the TCGA-BRCA cohort, patients were stratified into high (n = 541) and low (n = 542) RERE-AS1 expression groups. RERE-AS1 expression showed significant differences across several clinicopathological subgroups, including T stage (p = 1.1 × 10⁻3), pathological stage (p = 1.6 × 10⁻3), PR status (p = 0.01), HER2 status (p = 7.3 × 10⁻4), PAM50 molecular subtype (p < 0.05), radiotherapy status (p = 0.02), and histological type (p = 6 × 10⁻14). No statistically significant difference was observed in ER status (p = 0.07) (Fig. 2A–H). Univariate logistic regression further confirmed that RERE-AS1 expression was significantly associated with race (p = 0.007), PR status (p = 0.022), HER2 status (p = 0.031), radiotherapy (p = 0.021), and histological type (p < 0.001) (Table 3), but not with age, TNM stage, or ER status. Expression also differed among molecular subtypes, with notable variation in PR-positive and HER2-positive groups (Figure S1A, B). Stratified survival analysis revealed that in HER2-positive patients, high RERE-AS1 expression correlated with improved OS (HR = 0.25, 95% CI: 0.09–0.69, p = 0.007) (Fig. 2I), whereas no significant differences were observed in HER2-negative (p = 0.247) (Fig. 2J), or PR-stratified subgroups (p > 0.05) (Fig. 2K, D). Correlation Between RERE-AS1 Expression and Clinical Characteristics in BRCA Patients. A Comparison of RERE-AS1 expression across T stages in BRCA patients from the TCGA public database, analyzed using the Wilcoxon rank-sum test. B Comparison of RERE-AS1 expression across pathological stages in BRCA patients from the TCGA public database, analyzed using the Wilcoxon rank-sum test. C–H Associations between RERE-AS1 expression and C PR status, D ER status, E HER2 status, F PAM50 molecular subtypes, G histological types, and H radiotherapy status in BRCA patients from the TCGA public database, all evaluated using the Wilcoxon rank-sum test. I–L Kaplan–Meier survival curves of BRCA patients stratified by RERE-AS1 expression in HER2-positive I, HER2-negative J, PR-positive K, and PR-negative L subgroups Table 3Association between RERE-AS1 expression and clinicopathological characteristics of breast cancer patients in the TCGA dataset (n = 1083)CharacteristicsTotal (N)Odds ratio (OR)P valueAge (> 60 vs. < = 60)1,0831.140 (0.897–1.450)0.283Race (White vs. Asian and Black or African American)9941.096 (0.820–1.466)0.534Menopause status (Post vs. Pre and Peri)9721.135 (0.857–1.504)0.377T stage (T3 andT4 vs. T1 and T2)1,0801.052 (0.760–1.456)0.761N stage (N1 and N2 and N3 vs. N0)1,0640.913 (0.717–1.161)0.457M stage (M1 vs. M0)9220.713 (0.277–1.739)0.462Pathologic stage (Stage III and Stage IV vs. Stage I and II)1,0600.946 (0.715–1.251)0.696Histological type (Infiltrating Lobular Carcinoma vs. Infiltrating Ductal Carcinoma)9772.968 (2.141–4.157) < 0.001ER status (Positive vs. Negative)1,0331.129 (0.846–1.508)0.411PR status (Positive vs. Negative)1,0301.356 (1.045–1.760)0.022HER2 status (Positive vs. Negative)7150.675 (0.471–0.964)0.031Anatomic neoplasm subdivisions (Right vs. Left)1,0831.226 (0.966–1.557)0.094radiation_therapy (Yes vs. No)9871.347 (1.047–1.734)0.021The bold values indicates statistically significant results with p 0.05 Association between RERE-AS1 expression and clinicopathological characteristics of breast cancer patients in the TCGA dataset (n = 1083) The bold values indicates statistically significant results with p 0.05 Significant value of RERE-AS1 in the diagnosis and prognosis assessment of BRCA Based on the TCGA-BRCA cohort, patients were classified into high- and low-expression groups according to the median RERE-AS1 level. Kaplan–Meier analysis demonstrated that low RERE-AS1 expression was significantly associated with poorer OS (HR = 0.63, 95% CI: 0.46–0.87, p = 0.005), progression-free survival (PFS: HR = 0.64, p = 0.009), and disease-specific survival (DSS: HR = 0.49, p = 0.001) (Fig. 3A–C). ROC analysis indicated that RERE-AS1 achieved an AUC of 0.808 (95% CI: 0.770–0.847) in distinguishing BRCA from normal tissues and performed well across various clinical subgroups, with the highest AUC of 0.899 in the T4 stage (Fig. 3D–R). In the nomogram model, the C-index for predicting OS and RFS based on RERE-AS1 expression was 0.760 and 0.691, respectively, which is superior to the TNM staging system (OS: 0.698; RFS: 0.649) (Fig. 3S, T). In an independent cohort of patients (Luminal B, n = 137; triple-negative, n = 37), the high-expression group exhibited significantly prolonged OS (HR = 0.57, 95% CI: 0.38–0.85, p = 0.006) (Fig. 3U). Multivariate Cox regression analysis showed that high RERE-AS1 expression, age, TNM stage, pathological stage, and ER status were associated with OS, whereas PR and HER2 status were not statistically significant (Table 4). Prognostic and Diagnostic Value of RERE-AS1 Expression in BRCA. A–C Kaplan–Meier survival curves evaluating the association between RERE-AS1 expression levels and prognosis in BRCA patients from the TCGA-BRCA dataset, including A OS, B PFS, and C DSS. D–R ROC curves assessing the diagnostic performance of RERE-AS1 expression in distinguishing BRCA tissues from normal tissues and among tumors at different stages (X-axis: false positive rate; Y-axis: true positive rate). S Nomogram constructed to predict the 1, 3, and 5 year OS probabilities in BRCA patients based on RERE-AS1 expression; T corresponding calibration plot. U Association analysis of RERE-AS1 expression with OS in triple-negative and Luminal B subtype BRCA tissues. Survival analysis is conducted using the log-rank test, AUC evaluates diagnostic efficiency from ROC curves, and the nomogram model is constructed through regression analysis. Data are derived from the TCGA-BRCA public database Table 4Analysis of overall survival using cox proportional hazards regression modelCharacteristicstotal (N)Univariate analysisMultivariate analysishazard ratio (95% CI)P valuehazard ratio (95% CI)P valueAge1082< = 60601Reference> 604812.020 (1.465–2.784)< 0.0012.297 (1.571–3.359)< 0.001Race993Black or African American180ReferenceWhite7530.869 (0.578–1.307)0.501Asian600.656 (0.199–2.160)0.488T stage1079T1 and T2905ReferenceT3 and T41741.608 (1.110–2.329)0.0120.980 (0.576–1.670)0.942N stage1063N0514ReferenceN1 and N2 and N35492.239 (1.567–3.199)< 0.0011.536 (0.965–2.445)0.070M stage922M0902ReferenceM1204.254 (2.468–7.334)< 0.0012.464 (1.215–4.996)0.012Pathologic stage1059Stage I and Stage II799ReferenceStage III and Stage IV2602.391 (1.703–3.355)< 0.0012.121 (1.190–3.780)0.011ER status1034Negative240ReferencePositive7920.712 (0.495–1.023)0.0660.467 (0.314–0.696)< 0.001Indeterminate213.088 (3.128–54.771)< 0.0017.570 (0.995–57.580)0.051PR status1033Negative342ReferencePositive6870.732 (0.524–1.025)0.069Indeterminate40.826 (0.113–6.035)0.851HER2 status727Negative558ReferencePositive1571.593 (0.973–2.609)0.064Indeterminate120.000 (0.000–Inf)0.994Histological type977Infiltrating ductal carcinoma772Referenceinfiltrating Lobular carcinoma2050.827 (0.526–1.299)0.410RERE-AS11082Low541ReferenceHigh5410.631 (0.457–0.870)0.0050.694 (0.482–0.999)0.049The bold values indicates statistically significant results with p 0.05 Analysis of overall survival using cox proportional hazards regression model The bold values indicates statistically significant results with p 0.05 Molecular mechanisms and signaling pathways involving RERE-AS1 in BRCA progression Using the DESeq2 pipeline, differential expression analysis was performed on RNA sequencing data from the TCGA-BRCA cohort. GO enrichment analysis revealed that RERE-AS1 was primarily associated with RNA processing and spliceosome functions, including precursor mRNA binding, recognition of 5′ splice sites, snRNP complex formation, U2 snRNP assembly, and tetrameric snRNP complex organization (Fig. 4A). Functional Enrichment Analysis Related to RERE-AS1 Expression in BRCA. A Bubble plot showing the results of GO enrichment analysis for genes associated with RERE-AS1 expression. The X-axis represents the GeneRatio, the bubble size indicates the number of genes, and the color denotes the adjusted p-value (p.adj). B GSEA shows enrichment in immune-related pathways, including “adaptive immune response based on somatic recombination”, “antigen binding”, “antigen receptor-mediated signaling pathway”, “B cell activation”, and “B cell-mediated immunity” Further, GSEA revealed that RERE-AS1-associated genes were enriched in multiple immune-related pathways, including adaptive immune response, antigen binding, antigen receptor–mediated signaling, B cell activation, and B cell–mediated immune regulation (Fig. 4B). Association between RERE-AS1 expression and immune infiltration in BRCA To clarify the immune relevance of RERE-AS1 in BRCA, its correlation with immune cell infiltration was analyzed. Lollipop plots revealed a strong positive association between RERE-AS1 expression and several immune cell subsets, notably T helper 2 (Th2) cells (Fig. 5A). Spearman correlation combined with ssGSEA further confirmed that RERE-AS1 expression was positively correlated with the infiltration of activated dendritic cells (aDCs), B cells, CD8⁺ T cells, cytotoxic cells, eosinophils, immature DCs, macrophages, mast cells, neutrophils, and both CD56bright and CD56dim NK cells (Fig. 5B). Consistently, ESTIMATE analysis demonstrated significantly higher StromalScore, ImmuneScore, and ESTIMATEScore in the high RERE-AS1 expression group (Fig. 5C–E). Correlation Analysis Between RERE-AS1 Expression and Immune Cell Infiltration in BRCA. A Lollipop plot showing the correlation between RERE-AS1 expression and the infiltration levels of various immune cell types in BRCA tissues based on the TCGA public database. Immune cell types include Th2 cells, NK cells, CD8+ T cells, neutrophils, DCs, and B cells. B Comparison of immune cell infiltration levels between high- and low-RERE-AS1 expression groups in BRCA samples from the TCGA dataset.. C–E Distribution differences of StromalScore, ImmuneScore, and ESTIMATEScore calculated by the ESTIMATE algorithm between high and low RERE-AS1 expression groups RERE-AS1 the proliferation, motility, cell cycle progression, and apoptosis of BRCA Cells To establish a RERE-AS1 modulation model, sh-RERE-AS1 and sg-RERE-AS1 (KI) intervention systems were constructed in MCF-7 and T47D cells. RT-qPCR results showed that RERE-AS1 expression was significantly reduced in the sh-RERE-AS1-1, sh-RERE-AS1-2, and sh-RERE-AS1-3 groups compared to the sh-NC group, with sh-RERE-AS1-1 exhibiting the strongest knockdown effect. Conversely, RERE-AS1 expression was significantly increased in the sg-RERE-AS1 (KI)-1 and sg-RERE-AS1 (KI)-2 groups compared to the sg-NC (KI) group, with sg-RERE-AS1 (KI)-1 showing the highest overexpression. Therefore, sh-RERE-AS1-1, sh-RERE-AS1-2, sg-RERE-AS1 (KI)-1, and sg-RERE-AS1 (KI)-2 are selected for subsequent experiments in MCF-7 and T47D cells (Fig. 6A, Fig. S3A). Effects of RERE-AS1 on Cell Proliferation, Migration, Invasion, Cell Cycle, and Apoptosis in BRCA Cells A RT-qPCR analysis of RERE-AS1 knockdown and overexpression in MCF-7 cells. B CCK-8 assay evaluating the proliferation ability of MCF-7 cells in each group. C Transwell assay assessing the migration and invasion abilities of MCF-7 cells in each group. D Flow cytometry analysis of cell cycle distribution in MCF-7 cells across groups. E Flow cytometry analysis of apoptosis in MCF-7 cells across groups. F Western blot analysis of the expression levels of invasion- and migration-related markers (E-cadherin, N-cadherin, ZO-1, MMP2), cell cycle proteins (Cyclin A1, Cyclin B1, Cyclin D2), and apoptosis-related proteins (cleaved Caspase-3, Caspase-3, Bax, and Bcl-2). * indicates p < 0.05 compared with the sh-NC group; # indicates p < 0.05 compared with the sg-NC group. All cell experiments are repeated three times CCK-8 assays demonstrated that MCF-7 and T47D cells in the sh-RERE-AS1-1 and sh-RERE-AS1-2 groups exhibited higher OD values than the sh-NC group, indicating enhanced proliferation, whereas OD values were significantly reduced in sg-RERE-AS1 (KI)-1 and sg-RERE-AS1 (KI)-2 groups relative to sg-NC (KI) controls (Fig. 6B, Fig. S3B). Transwell assays further confirmed that silencing RERE-AS1 promoted, while its overexpression inhibited, the migratory and invasive capacities of both cell lines (Fig. 6C, Fig. S3C). Flow cytometric analysis showed that RERE-AS1 overexpression in MCF-7 and T47D cells (sg-RERE-AS1 (KI)-1 and sg-RERE-AS1 (KI)-2) increased the proportion of cells in the G0/G1 phase and reduced those in the S phase, indicating cell-cycle arrest. Conversely, RERE-AS1 knockdown (sh-RERE-AS1-1 and sh-RERE-AS1-2) produced the opposite effect (Fig. 6D, Fig. S3D). Apoptosis assays revealed that the apoptotic rate was significantly lower in sh-RERE-AS1 cells and higher in sg-RERE-AS1 (KI) cells compared with their respective controls (Fig. 6E, Fig. S3E). Western blot analysis indicated that in MCF-7 and T47D cells, the sg-RERE-AS1 (KI)-1 and sg-RERE-AS1 (KI)-2 groups upregulated E-cadherin, ZO-1, cleaved Caspase-3, and Bax, while downregulating N-cadherin, MMP2, Cyclin A1, Cyclin B1, Cyclin D2, and Bcl-2. The sh-RERE-AS1-1 and sh-RERE-AS1-2 groups displayed opposite expression patterns (Fig. 6F, Fig. S3F). Overexpression of RERE-AS1 inhibits tumor cell-mediated immune infiltration and immune evasion Transwell assays revealed that immune cell migration was markedly reduced after coculture with sh-RERE-AS1-1 or sh-RERE-AS1-2 MCF-7 and T47D cells, whereas migration was significantly enhanced following coculture with sg-RERE-AS1 (KI)-1 or sg-RERE-AS1 (KI)-2 cells (Fig. 7A, Fig. S4A). Effects of RERE-AS1 on Immune Evasion of MCF-7 Cells. A Transwell assay evaluating the migratory capacity of immune cells in different co-culture systems. B LDH release assay assessing immune cell-mediated cytotoxicity against MCF-7 cells in each co-culture group. C ELISA analysis of IFN-γ, TNF-α, and IL-10 secretion levels by immune cells in each co-culture system. D Flow cytometry analysis of immune cell subtype proportions in each co-culture system. * indicates p < 0.05 compared with the sh-NC group; # indicates p < 0.05 compared with the sg-NC (KI) group. All cell experiments are repeated three times LDH release assays showed that LDH activity was significantly reduced in sh-RERE-AS1-1 and sh-RERE-AS1-2 MCF-7 and T47D cocultures compared with sh-NC, whereas it was markedly elevated in sg-RERE-AS1 (KI)-1 and sg-RERE-AS1 (KI)-2 cocultures relative to sg-NC (KI), indicating enhanced immune cytotoxicity following RERE-AS1 overexpression (Fig. 7B, Fig. S4B). Consistently, ELISA assays demonstrated decreased IFN-γ and TNF-α secretion with increased IL-10 levels in RERE-AS1-silenced cocultures, whereas RERE-AS1 overexpression reversed these cytokine patterns (Fig. 7C, Fig. S4C). Flow cytometry analysis revealed that in MCF-7 or T47D coculture systems, the numbers of NK cells (CD16+/CD56+), B cells (CD19+/CD20+), M1 macrophages (CD80+/CD86+), and DCs (CD11c+/CD141+) were decreased, while M2 macrophages (CD163+/CD206+) were increased in the sh-RERE-AS1-1 and sh-RERE-AS1-2 groups. In contrast, opposite trends were observed in the sg-RERE-AS1(KI)-1 and sg-RERE-AS1(KI)-2 groups (Fig. 7D, Fig. S4D). Sensitivity of RERE-AS1 to αPD-1 and its potential clinical application value Tumor growth analysis revealed that xenografts in the sh-RERE-AS1 + anti-IgG group exhibited accelerated growth and increased weight compared with the sh-NC + anti-IgG group, whereas the sg-RERE-AS1 (KI) + anti-IgG group showed markedly slower growth and lower tumor weight relative to sg-NC (KI) + anti-IgG. Under αPD-1 treatment, similar trends were observed: tumors were larger in the sh-RERE-AS1 + αPD-1 group and smaller in the sg-RERE-AS1 (KI) + αPD-1 group compared with their respective controls. No significant difference was detected between sh-RERE-AS1 + αPD-1 and sh-RERE-AS1 + anti-IgG, whereas the combination of sg-RERE-AS1 (KI) with αPD-1 further reduced tumor volume and weight, indicating that RERE-AS1 overexpression enhances sensitivity to PD-1 blockade (Fig. 8A, B). Evaluation of RERE-AS1 Sensitivity to αPD-1. A A BRCA xenograft model was established by subcutaneously injecting pretreated MCF-7 cells. Tumor volume was measured every 3 days to generate growth curves of BRCA xenografts. B Tumor weights were recorded after the euthanasia of the mice. C Immunohistochemical staining was performed to evaluate Ki-67 expression levels in mouse tumor tissues. D Flow cytometry assessed cell cycle distribution in tumor cells from each group. E Flow cytometry analysis of apoptosis in tumor cells across treatment groups. * indicates p < 0.05 compared with the sh-NC + anti-IgG group; # indicates p < 0.05 compared with the sg-NC (KI) + anti-IgG group; @ indicates p < 0.05 compared with the sh-NC + αPD-1 group; ^ indicates p < 0.05 compared with the sg-NC (KI) + αPD-1 group; $ indicates p < 0.05 compared with the sg-RERE-AS1 (KI) + anti-IgG group. Each group included 5 mice Immunohistochemical analysis showed markedly elevated Ki-67 expression in the sh-RERE-AS1 + anti-IgG group compared with the sh-NC + anti-IgG group, whereas Ki-67 levels were significantly reduced in the sg-RERE-AS1 (KI) + anti-IgG group relative to sg-NC (KI) + anti-IgG. Under αPD-1 treatment, Ki-67 expression increased in the sh-RERE-AS1 + αPD-1 group and significantly decreased in the sg-RERE-AS1 (KI) + αPD-1 group. No significant difference was observed between the sh-RERE-AS1 + αPD-1 and sh-RERE-AS1 + anti-IgG groups, while Ki-67 expression was further reduced in the sg-RERE-AS1 (KI) + αPD-1 group compared to the sg-RERE-AS1 (KI) + anti-IgG group (Fig. 8C). Flow cytometric analysis following PI staining demonstrated that cells in the sg-RERE-AS1 (KI) + αPD-1 group exhibited pronounced G0/G1 phase arrest with a corresponding decrease in S phase cells, whereas the sh-RERE-AS1 + anti-IgG and sh-RERE-AS1 + αPD-1 groups displayed an opposite trend, characterized by an increased S phase fraction and reduced G0/G1 population. No significant difference was observed in cell cycle distribution between the sh-RERE-AS1 + αPD-1 and sh-RERE-AS1 + anti-IgG groups, whereas G0/G1 arrest was more pronounced in the sg-RERE-AS1 (KI) + αPD-1 group compared to the sg-RERE-AS1 (KI) + anti-IgG group (Fig. 8D). Annexin V-based flow cytometry analysis of apoptosis showed that the apoptotic rate was lower in the sh-RERE-AS1 + anti-IgG and sh-RERE-AS1 + αPD-1 groups compared to their respective control group (sh-NC). In contrast, the apoptotic rate was higher in the sg-RERE-AS1 (KI) + anti-IgG and sg-RERE-AS1 (KI) + αPD-1 groups compared to the sg-NC group. No significant change was observed between the sh-RERE-AS1 + αPD-1 and sh-RERE-AS1 + anti-IgG groups, whereas the apoptotic rate was further increased in the sg-RERE-AS1 (KI) + αPD-1 group compared to the sg-RERE-AS1 (KI) + anti-IgG group (Fig. 8E). Discussion BRCA remains one of the most prevalent malignancies globally, with high mortality and unsatisfactory prognosis [19–21]. Its steadily increasing incidence imposes a substantial economic burden on patients, families, and society [22]. Thus, identifying novel molecular biomarkers for early detection, prognostic assessment, and therapeutic response prediction, together with the development of effective targeted therapies, holds critical clinical significance. Long non-coding RNAs (lncRNAs) exhibit aberrant expression across multiple cancer types and serve as key regulators of tumor initiation and progression [23]. Several tumor-suppressive lncRNAs are downregulated in different malignancies, and their loss promotes tumor progression [24]. Mechanistically, lncRNAs may exert tumor-suppressive functions by negatively regulating glycolysis-related genes [25] or modulating DNA, RNA, and protein expression [26]. RERE-AS1, as a lncRNA, remains insufficiently characterized, and its functional and clinical significance in BRCA is largely unexplored. In this study, RERE-AS1 expression was comprehensively analyzed across multiple cancer types, revealing significant downregulation in BRCA, with predominant cytoplasmic localization. Its expression correlated closely with tumor stage, hormone receptor status, and PAM50 molecular subtype. Survival analysis showed that elevated RERE-AS1 expression was associated with longer OS, DSS, and PFI, while Cox regression confirmed its independent prognostic value. ROC and nomogram analyses further demonstrated its diagnostic and predictive potential. Compared with its variable expression in KICH, KIRC, and LUSC, RERE-AS1 exhibited more consistent and biologically relevant patterns in BRCA, where high expression was linked to early-stage disease and favorable prognosis [27]. Our integrated multi-omics and experimental validation highlight the potential role and clinical relevance of RERE-AS1 in BRCA. From an immunological perspective, RERE-AS1 exerts critical functions. Transcriptomic and immune infiltration analyses revealed that its high expression was positively associated with increased infiltration of aDCs, B cells, CD8+ T cells, and NK cells, accompanied by elevated immune/stromal scores. Functional assays demonstrated that RERE-AS1 upregulation enhanced immune cell migration and cytotoxic activity, elevated IFN-γ and TNF-α levels while reducing IL-10 expression; in humanized mouse models, RERE-AS1 upregulation not only inhibited tumor growth but also synergized with αPD-1 treatment, suggesting a role in reshaping a “hot" immune microenvironment and reducing immune evasion. Enrichment analysis further indicated that its associated gene sets were enriched in antigen receptor signaling, B-cell activation, and adaptive immune responses, supporting a working model in which RERE-AS1 upregulation promotes the recruitment and activation of effector immune cells, thereby inhibiting tumor progression and enhancing ICI response [28]. Pan-cancer analysis showed that RERE-AS1 is significantly downregulated in COAD, KICH, LIHC, LUSC, PRAD, and THCA, but upregulated in KIRC, indicating tumor-type specificity. In KIRC, its upregulation may be associated with immune-suppressive niches and ICI resistance [29]; in LUSC, downregulation may impair antigen presentation and immune lineage composition [30]; in HCC, low expression may contribute to immune tolerance and vascular immune barriers [31]; while in THCA, reduced expression may affect macrophage and dendritic cell lineages [32]. Consistent with prior studies, RERE-AS1 has been reported to suppress malignant phenotypes through the MEK/ERK pathway in BRCA and exhibits diagnostic and prognostic potential across multiple cancers [27], aligning with our observation that its high expression correlates with smaller tumor size and earlier disease stage in BRCA. As a natural antisense lncRNA, the upstream regulation of RERE-AS1 may involve neighboring gene interactions and epigenetic mechanisms, including promoter methylation and chromatin remodeling, which represent common regulatory modes of antisense lncRNAs [33]. Moreover, the RERE gene itself functions as a co-regulator of retinoic acid signaling, suggesting a possible cis-regulatory linkage between RERE-AS1 and RA signaling [34]. Downstream, RERE-AS1 has been shown to suppress malignant phenotypes via inhibition of the MEK/ERK pathway and enhance sensitivity to CDK4/6 inhibitors [27], consistent with our findings of increased E-cadherin and pro-apoptotic proteins and decreased N-cadherin/MMP2 upon its upregulation. Enrichment analysis also revealed associations with antigen receptor signaling and adaptive immune pathways, while functional assays confirmed its role in promoting IFN-γ/TNF-α production and suppressing IL-10, thereby enhancing NK and CD8+ T cell activity and synergizing with αPD-1 therapy. These results suggest that its downstream effects extend beyond EMT inhibition and cell-cycle arrest to include remodeling of the tumor immune microenvironment, consistent with the consensus that immune-related biomarkers can predict ICI response [35, 36]. Additional mechanisms may involve ceRNA activity relieving miRNA suppression of immune-related genes [37], or interactions with RNA-binding proteins/epigenetic regulators to upregulate antigen presentation and chemokine genes such as MHC-I/II and CXCL9/10 [38]. Furthermore, exosomes as nanoscale delivery vehicles may facilitate RERE-AS1 transfer to immune cells or tumor tissues, highlighting its potential in exosome-based targeted therapy for BRCA [39]. Although this study provides valuable insights into the role of RERE-AS1 in BRCA, several limitations should be acknowledged. First, the in vitro validation was limited to specific BRCA cell lines, and further studies involving additional cell models and in vivo experiments are required to substantiate these findings. Second, the downstream molecular targets and mechanisms of RERE-AS1 remain incompletely understood, and further molecular biology experiments are required to elucidate its precise functional roles in BRCA. Additionally, our analyses primarily rely on data from public databases, where variations may influence sample handling, experimental platforms, and data processing methods. Therefore, independent prospective studies are necessary to validate and extend our findings. The role of RERE-AS1 in BRCA and its potential as a biomarker suggest that it may represent a valuable direction for future research and therapeutic development. Future studies should focus on elucidating the detailed molecular mechanisms of RERE-AS1, identifying its downstream effectors and signaling pathways, and validating its clinical relevance in larger, independent cohorts and animal models. In addition, the relationship between RERE-AS1 and immune cell infiltration and its potential role in BRCA immunotherapy warrants further investigation. Overall, RERE-AS1 is significantly downregulated in breast tumors, and higher RERE-AS1 expression is associated with favorable outcomes. By modulating immune cell infiltration, RERE-AS1 may contribute to reduced BRCA incidence and progression, making it a promising prognostic marker and potential immunotherapeutic target. Through the integration of large-scale bioinformatics analyses and in vitro experimental validation, our study highlights the critical role and potential clinical value of RERE-AS1 in BRCA. These findings lay the groundwork for future exploration of RERE-AS1 in other cancer types and support its development as a potential therapeutic target. Supplementary Information Below is the link to the electronic supplementary material. Figure S1. RERE-AS1 Expression Across Different BRCA Subtypes. Note: (A) Schematic diagram showing the knock-in sequences of sg-RERE-AS1 (KI)-1 and sg-RERE-AS1 (KI)-2 and their genomic localization. (B) Violin plots displaying RERE-AS1 expression levels (log2[TPM+1]) in BRCA tissues from the TCGA public database, grouped by PR, ER, and HER2 status. Statistical analysis is performed using the Wilcoxon rank-sum test. **p < 0.01 compared with the negative group; ns indicates no statistically significant difference. White dots represent medians, black bars indicate the interquartile range, and the width of the violin reflects the density distribution of expression levels Figure S2. Analysis of RERE-AS1 expression across multiple cancer types. Note: (A-C) Expression profiles of RERE-AS1 based on (A) unpaired samples from 33 cancer types in the TCGA database, (B) unpaired samples from 33 cancer types in the TCGA-GTEx dataset, and (C) 18 paired tumor and adjacent normal tissues in the TCGA cohort Figure S3. Effects of RERE-AS1 on Proliferation, Migration, Invasion, Cell Cycle, and Apoptosis in T47D BRCA Cells. Note: (A) RT-qPCR analysis of RERE-AS1 knockdown and overexpression in T47D cells. (B) CCK-8 assay evaluating the proliferation ability of T47D cells in each group. (C) Transwell assay assessing the migration and invasion abilities of T47D cells across groups. (D) Flow cytometry analysis of cell cycle distribution in T47D cells. (E) Flow cytometry analysis of apoptosis in T47D cells. (F) Western blot analysis of invasion- and migration-related markers (E-cadherin, N-cadherin, ZO-1, MMP2), cell cycle proteins (Cyclin A1, Cyclin B1, Cyclin D2), and apoptosis-related proteins (cleaved Caspase-3, Caspase-3, Bax, Bcl-2). * indicates p < 0.05 compared with the sh-NC group; # indicates p < 0.05 compared with the sg-NC group. All cell experiments were performed in triplicate Figure S4. Effects of RERE-AS1 on Immune Evasion of T47D cells. Note: (A) Transwell assay evaluating the migratory capacity of immune cells in different co-culture systems. (B) LDH release assay assessing immune cell-mediated cytotoxicity againstT47D cells in each co-culture group. (C) ELISA analysis of IFN-γ, TNF-α, and IL-10 secretion levels by immune cells in each co-culture system. (D) Flow cytometry analysis of immune cell subtype proportions in each co-culture system. * indicates p < 0.05 compared with the sh-NC group; # indicates p < 0.05 compared with the sg-NC (KI) group. All cell experiments are repeated three times Supplementary file5 (DOCX 18 KB) Supplementary file6 (DOCX 18 KB) Supplementary file7 (DOCX 18 KB) Supplementary file8 (DOCX 17 KB) Abbreviations Activated dendritic cells Analysis of variance American type culture collection Breast cancer Biological processes Cellular components Cell counting kit-8 Confidence intervals Differentially expressed genes Dendritic cells Disease metastasis-free survival Disease-specific survival Event-free survival Enzyme-linked immunosorbent assay Fetal bovine serum False discovery rate Fluorescence in situ hybridization Gene set enrichment analysis Gene ontology Human peripheral blood mononuclear cells Hazard ratios Kyoto encyclopedia of genes and genomes Lactate dehydrogenase Long non-coding RNA Molecular functions Multiplicity of infection Molecular signatures database Natural killer Overall survival Peripheral blood mononuclear cells Patient-derived xenograft Progression-free interval Progression-free survival Pathological complete response Propidium iodide Phenylmethanesulfonyl fluoride Quantitative reverse transcription polymerase chain reaction Relapse-free survival Receiver operating characteristic Regularized log Single guide RNAs Specific pathogen-free Single-sample gene set enrichment analysis Short tandem repeat The cancer genome atlas T helper 2 Tumor-infiltrating lymphocytes Tumor microenvironment Variance-stabilizing transformation Author contributions Pengfei Luo, Wenjie Feng, and Weijie He conceived and designed the study. Shaohui Jiang and Lunqi Luo conducted the experiments. Lijun Zeng, Yuanbing Tang, and Meilin Wen analyzed the data. Yuehua Li and Yongjun Jiang supervised the research and provided critical revisions. Pengfei Luo, Wenjie Feng, and Weijie He drafted the manuscript, with all authors contributing to and approving the final version of the manuscript. Funding This investigation was supported by grants from Natural Science Foundation of Hunan Province (No. 2025JJ80098), Scientific Research Fund Project of Hunan Provincial Health Commission( No.D202303109439) and Clinical Medical Research 4310 Program of the University of South China ( No.20224310NHYCG07). Data availability The data that supports the findings of this study are available on request from the corresponding author upon reasonable request. Declarations Conflict of interest The authors declare no competing interests. Ethics approval and consent to participate Ethical considerations were strictly followed throughout the study. All data and samples collected adhered to the approved experimental protocol by the First Affiliated Hospital, Hengyang Medical School, University of South China ethical committee. Informed consent was obtained from all participating patients. Footnotes Shaohui Jiang, Weijie He, and Zhimin Li are regarded as co-first authors. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Meiling Wen, Email: wmlwml97@163.com. Hongbo Zhu, Email: zhuhb_2023@usc.edu.cn. Pengfei Luo, Email: pengfeiluo1987@163.com. References Associated Data Supplementary Materials Figure S1. RERE-AS1 Expression Across Different BRCA Subtypes. Note: (A) Schematic diagram showing the knock-in sequences of sg-RERE-AS1 (KI)-1 and sg-RERE-AS1 (KI)-2 and their genomic localization. (B) Violin plots displaying RERE-AS1 expression levels (log2[TPM+1]) in BRCA tissues from the TCGA public database, grouped by PR, ER, and HER2 status. Statistical analysis is performed using the Wilcoxon rank-sum test. **p < 0.01 compared with the negative group; ns indicates no statistically significant difference. White dots represent medians, black bars indicate the interquartile range, and the width of the violin reflects the density distribution of expression levels Figure S2. Analysis of RERE-AS1 expression across multiple cancer types. Note: (A-C) Expression profiles of RERE-AS1 based on (A) unpaired samples from 33 cancer types in the TCGA database, (B) unpaired samples from 33 cancer types in the TCGA-GTEx dataset, and (C) 18 paired tumor and adjacent normal tissues in the TCGA cohort Figure S3. Effects of RERE-AS1 on Proliferation, Migration, Invasion, Cell Cycle, and Apoptosis in T47D BRCA Cells. Note: (A) RT-qPCR analysis of RERE-AS1 knockdown and overexpression in T47D cells. (B) CCK-8 assay evaluating the proliferation ability of T47D cells in each group. (C) Transwell assay assessing the migration and invasion abilities of T47D cells across groups. (D) Flow cytometry analysis of cell cycle distribution in T47D cells. (E) Flow cytometry analysis of apoptosis in T47D cells. (F) Western blot analysis of invasion- and migration-related markers (E-cadherin, N-cadherin, ZO-1, MMP2), cell cycle proteins (Cyclin A1, Cyclin B1, Cyclin D2), and apoptosis-related proteins (cleaved Caspase-3, Caspase-3, Bax, Bcl-2). * indicates p < 0.05 compared with the sh-NC group; # indicates p < 0.05 compared with the sg-NC group. All cell experiments were performed in triplicate Figure S4. Effects of RERE-AS1 on Immune Evasion of T47D cells. Note: (A) Transwell assay evaluating the migratory capacity of immune cells in different co-culture systems. (B) LDH release assay assessing immune cell-mediated cytotoxicity againstT47D cells in each co-culture group. (C) ELISA analysis of IFN-γ, TNF-α, and IL-10 secretion levels by immune cells in each co-culture system. (D) Flow cytometry analysis of immune cell subtype proportions in each co-culture system. * indicates p < 0.05 compared with the sh-NC group; # indicates p < 0.05 compared with the sg-NC (KI) group. All cell experiments are repeated three times Supplementary file5 (DOCX 18 KB) Supplementary file6 (DOCX 18 KB) Supplementary file7 (DOCX 18 KB) Supplementary file8 (DOCX 17 KB) Data Availability Statement The data that supports the findings of this study are available on request from the corresponding author upon reasonable request.